Table 1.
Baseline characteristics according to urinary albumin levels during the (a) 2-year or (b) 3-year baseline period.
Fig 1.
Distribution of percent changes in eGFR during the (a) 2-year or (b) 3-year baseline period. Percent change in eGFR was calculated as (last eGFR at baseline period–first available eGFR) / (first available eGFR) * 100.
Table 2.
Baseline characteristics according to percent changes in eGFR during the (a) 2-year or (b) 3-year baseline period.
Fig 2.
Adjusted hazard ratios of end-stage renal disease according to percent changes in eGFR during the (a) 2-year or (b) 3-year baseline period. The model was adjusted for gender, age, systolic blood pressure, baseline eGFR, baseline urinary albumin, and history of cardiovascular disease. Knots were placed at −53%, −25%, −10%, and 10%. A reference point was set at 0% change in eGFR. Value trimmed at less than −70% and >10% change in eGFR.
Fig 3.
Adjusted hazard ratios of end-stage renal disease according to percent changes in eGFR during the (a) 2-year or (b) 3-year baseline period in subgroup analysis based on baseline urinary albumin levels. The model was adjusted with gender, age, systolic blood pressure, baseline eGFR, baseline urinary albumin, and history of cardiovascular disease. Knots were placed at −53%, −25%, −10%, and 10%. A reference point was set at 0% change in eGFR. Value trimmed at less than −70% and >10% change in eGFR.
Fig 4.
Percent population attributable risk (%PAR) of end-stage renal disease associated with percent changes in eGFR during the (a) 2-year or (b) 3-year baseline period.
Table 3.
Positive predictive value (PPV) with 95% confidence interval for end-stage renal disease according to percent changes in eGFR during the 2-year and 3-year baseline periods.
Fig 5.
Adjusted hazard ratios of all-cause mortality according to percent changes in eGFR during the (a) 2-year or (b) 3-year baseline period. The model was adjusted for gender, age, systolic blood pressure, baseline eGFR, baseline urinary albumin, and history of cardiovascular disease. Knots were placed at −53%, −25%, −10%, and 10%. A reference point was set at 0% change in eGFR. Value trimmed at less than −70% and >10% change in eGFR.